MundodeHoy.com - Mariana Chavez Mac Gregor, MD, MSC
Inicio | Noticias | Opinión | Mariana Chavez Mac Gregor, MD, MSC

Mariana Chavez Mac Gregor, MD, MSC

Por
Foto: MD Anderson Cancer Center Foto: MD Anderson Cancer Center

Bio Profesional

PRESENT TITLE AND AFFILIATION

Primary Appointment 

Associate Professor, Tenure Track, Department of Health Services Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

EDUCATION

Degree-Granting Education

Universidad Nacional Autónoma de México, Facultad de Medicina, Mexico City, Mexico, MD, 2003, Medicine

Netherlands Institute of Health and Sciences, Rotterdam, Netherlands, MSc, 2004, Clinical Epidemiology

Postgraduate Training

Clinical Internship, Internal Medicine, Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO, 7/2005-6/2006

Clinical Residency, Internal Medicine, Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO, 7/2006-6/2008

Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2008-6/2011

CREDENTIALS

Board Certification

Internal Medicine, 293632, 2008-2018

Medical Oncology, 293632, 11/2011-2021

Medical Oncology (Mexican Board of Oncology), 5/2016-5/2021

Licensures

Active

Physician Surgeon, Mexico, 3838420, 2/2002

TX, P2211, 2012

Inactive

N/A

EXPERIENCE/SERVICE

Academic Appointments

Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2011-9/2017

Assistant Professor, Tenure track, Department of Health Services Research, Division of Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2014-9/2017

Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2017-present

Associate Professor, Tenure Track, Department of Health Services Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2017-present

Administrative Appointments/Responsibilities

N/A

Other Appointments/Responsibilities

Study Coordinator, Departamento de Oncología, Instituto Nacional de Nutrición Salvador Zubirán, Mexico City, Mexico, 8/2004-5/2005

Medicine Chief Resident, John Cochran VA Medical Center, St. Louis, MO, 6/2007-1/2008

Member, SWOG Breast Committee, Portland, OR, 2011-present

Member, SWOG Breast Committee Working Group, Portland, OR, 2011-present

Member, National Breast Cancer Guideline Committee, Mexico, Mexico, 2012-present

Member, ASCO representative in the Consensus Guideline on margins for invasive breast cancer, SSO/ASTRO, 2013-2014

Member, SWOG Cost-Effectiveness and Outcomes Committee, Portland, OR, 10/2013-present

Member, ASCO Clinical Practice Guideline Committee, Alexandria, VA, 5/2014-6/2017

Liaison Member, ASCO Quality of Care Committee, Alexandria, VA, 7/2014-6/2017

Member, ASCO Guideline Methodology Subcommittee, Alexandria, VA, 7/2014-present

Member, ASCO Representative in the Consensus Guideline on margins for ductal carcinoma in situ cancer, ASCO/SSO/ASTRO, 2015-2016

Member, SWOG CCDR Database Observational Study Working Group, 2015-present

Member, NCCN Foundation Young Investigator Award Review Committee, 2016-present

MD Anderson Physician Network Consultant, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2016-present

Chair Elect, ASCO Clinical Practice Guidelines Committee, Houston, TX, 7/2017-6/2018

Chair, ASCO Clinical Practice Guidelines, Houston, TX, 6/2018-present

Endowed Positions

N/A

Consultantships

N/A

Military or Other Governmental Service

N/A

Institutional Committee Activities

Clinical Research Committee 3, Member, 8/2008-8/2012

MD Anderson Cancer Center at Cooper (MDACCC) Relationship Committee, Member, 2014-present

Mexican American Cohort Internal Advisory Board, Member, 2014-present

Multidisciplinary Breast Cancer Relationship Committee, Member, 2014-present

Charles A. LeMaistre Lecture, Nomination Committee, 8/2015-8/2017

Clinical Effectiveness Subcommittee (CE Subcommittee), Member, 8/2015-present

Department of Health Services Research Faculty Search Committee, Member, 10/2015-7/2017

Health Services Research Monthly Seminar, Program Coordinator, 2016-present

Faculty Senate, Senator, 9/2016-8/2019

Institutional Review Board IV, Member, 9/2016-present

Multidisciplinary Breast Evaluation Group Northwell, Medical Oncology Representative, 2017-present

Israelita Brasileira Hospital Albert Einstein Breast Tumor Board, Medical Oncology Advisor, 2017-present

MD Anderson Cancer Center Patient Advocate Initiative, Medical Oncology Leader Liaison, 2017-present

Symptom Research Chair Search Committee, Member, 2017-present

Chair Symptom Control Search Committee, Member, 2017

HONORS AND AWARDS

Academic Distinction, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, 2001

Achievement Medical Student Award, Universidad Nacional Autónoma de México, 2002

Merit-based Academic CONACYT Scholarship, The National Council for Science and Technology. Mexico, 2003

NIHES Award, Erasmus University Rotterdam, University of Amsterdam, Utrecht University, University of Nijmegen, National Institute of Public Health and Environment, Netherlands Cancer Institute, 2004

Best Poster Award, Mentors in Medicine Research Grant Scientific Symposium. Washington University School of Medicine, 2006

Clinical Scientist Training and Research Program, Barnes Jewish Hospital, Washington University School of Medicine, St. Louis, MO., 2006

Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 2008

Kipnis-Daughaday Teaching Award, Washington University School of Medicine, 2008

AACR Minority Scholar Award, Susan G. Komen for the Cure, 2009

Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 2009

ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium, 2009

Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 2010

ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium, 2010

Selected for participation at the AACR/ASCO Methods in Clinical Cancer Research Workshop, Vail, Colorado, 2010

Achievement in Clinical Research Award, The Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 2011

ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium, 2011

Young Investigator Award, SWOG, 2011

Young Investigator Award, Multinational Association of Supportive Care in Cancer (MASCC), 2015

Top 1% Nationally in CAHPS measures related to patient experience and satisfaction, The University of Texas MD Anderson Cancer Center, 2017

Conquer Cancer Foundation Advanced Clinical Research Award in Breast Cancer, ASCO, 2018

2018 Faculty Scholar Award, The University of Texas MD Anderson Cancer Center, 2018

ASCO Leadership Development Program, ASCO, 2018-present

RESEARCH

Grants and Contracts

Funded

Co-Investigator, 15%, Toxicities of Breast Cancer Treatment, SAC150061, Susan G. Komen Breast Cancer Foundation, PI - Sharon Giordano, 9/1/2015-8/31/2018, $480,000 ($160,000/year)

Co-Investigator, 10%, Comparative Effectiveness Research on Cancer in Texas (CERCIT) 2.0:  Project 2, RP160674, Cancer Prevention Research Institute of Texas (CPRIT) Subcontract with UT Medical Branch - Galveston, PI - James Goodwin, 8/31/2016-8/30/2021, $653,150 ($138,310/year)

Principal Investigator, 3%, Association of Body Mass Index (BMI) with emergency room visits and chemotherapy-related hospitalizations among breast cancer patients treated in SWOG clinical trials, NCORP Cancer Care Delivery and The Hope Foundation, 4/1/2018-3/31/2019, $25,000 ($25,000/year)

Principal Investigator, 20%, Understanding barriers and decreasing the time to chemotherapy in a vulnerable population: Pilot study of a targeted intervention, Conquer Cancer Foundation of the American Society of Clinical Oncology, 7/1/2018-6/30/2021 ($137,589/year)

Pending

Co-Investigator, 5%, Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications, 1 R01 CA225647-01, NIH, PI - Shih, 12/1/2018-11/30/2023, $1,523,103 ($314,369/year)

Other

N/A

Completed

Research Scholar, CERCIT: Comparative Effectiveness Research on Cancer in Texas, RP101207, Cancer Prevention & Research Institute of Texas (CPRIT), PI - James Goodwin, 8/1/2010-7/31/2012, $135,000 ($45,000/year)

Co-Investigator, 2%, CERCIT: Comparative Effectiveness Research on Cancer in Texas (P4: Quality of Supportive Care in Texas), RP140020-P4, Cancer Prevention & Research Institute of Texas (CPRIT), PI - James Goodwin, 3/1/2014-8/29/2016, $489,116 ($244,558/year)

Principal Investigator, 5%, Impact of Oncotype Dx testing on the timing of radiation therapy delivery among breast cancer patients: A population based study, 2015-13015201-Y1, The Center for Radiation Oncology - Health Services Research Seed Grant, 5/1/2015-9/30/2016, $15,000

Principal Investigator, 3%, Racial Disparities among participants in SWOG randomized clinical trials. NCORP Cancer Care Delivery Pilot Award, The Hope Foundation, 1/5/2016-1/5/2017, $25,000 ($25,000/year)

Co-Investigator, 2%, Health Assessment to Advance Cancer Prevention, Screening, and Control in the MD Anderson Cancer Center's Catchment Area: The State of Texas, 3 P30 CA016672-41S6, NIH/NCI, PI - Ronal DePinho, 9/1/2016-8/31/2017, $125,000 ($125,000/year)

Not Funded

Principal Investigator, PI3K/AKT/mTOR-related protein expression in breast cancer between White, Mexican and Mexican-American women, American Society of Clinical Oncology (ASCO) Young Investigator Award, 2010

Principal Investigator, Adherence, chemotherapy use and cardiac monitoring during adjuvant trastuzumab, National Comprehensive Cancer Network (NCCN) Young Investigator Award, 2011

Principal Investigator, Disparities in the Adherence, monitoring and toxicities of adjuvant trastuzumab, Susan G. Komen for the Cure Catalyst Award on Disparities, 2011

Principal Investigator, Trastuzumab-related cardiotoxicity, American Society of Clinical Oncology (ASCO) Young Investigator Award, 2011

Principal Investigator, Adherence to oral therapy in a phase III randomized placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high risk hormone receptor-positive and Her2-negative breast cancer (S1207), American Society of Clinical Oncology (ASCO) Cancer Foundation Career Development Award, 2013

Principal Investigator, 20%, Adherence to oral therapy in a phase III randomized placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high risk hormone receptor-positive and Her2-negative breast cancer (S1207), American Society of Clinical Oncology (ASCO) Career Investigator Award, 7/1/2014-7/1/2017 ($61,000/year)

Co-Investigator, 8%, Medical and Financial Toxicity among Patients with Breast Cancer: A Comparative Effectiveness Analysis, Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO), PI - Sharon Giordano, 7/1/2015-6/30/2020, $475,000 ($95,000/year)

Co-Investigator, 5%, Finding Optimal Strategies to Manage Cardiotoxicity in Elderly Cancer Patients, NIH, PI - Ya-Chen Tina Shih, 9/1/2015-8/31/2019, $745,073 ($174,565/year)

Principal Investigator, 20%, Clinical trial participation among older breast cancer patients, Susan G. Komen for the Cure. Career Catalyst Award, 7/1/2016-6/30/2019, $358,086 ($119,590/year)

Co-Investigator, 15%, Predictive modeling for the risk of cancer using large scale electronic health records, Cancer Prevention Research Institute of Texas (CPRIT) - Subcontract with UTHSC - Houston, PI - Hua Xu / Sharon Giordano, 12/1/2016-8/31/2019, $284,533 ($94,690/year)

Principal Investigator, 25%, Clinical trial participation among older breast cancer patients, MDACC - Sabin Foundation, 4/1/2017-3/31/2019, $99,954 ($52,850/year)

Principal Investigator, 20%, Clinical trial participation among older breast cancer patients, American Cancer Society (ACS), 7/1/2017-6/30/2021, $665,652 ($164,143/year)

Co-Investigator, 5%, Innovative machine learning methods in medical cost analysis, NIH - Subcontract from Northwestern University, PI - Ya-Chen Tina Shih/, 7/1/2017-6/30/2021, $350,167 ($70,332/year)

Protocols

Funded

Principal Investigator, Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer, SWOGS0307, 2006-present

Collaborator, Quality of Supportive Cancer Care in Texas, DR10-0685, PI - Linda S Elting, 2010-present

Collaborator, Phase Ib Trial Of The Combination Of PI3K Inhibitor BAY 80-6946 And Allosteric-MEK Inhibitor BAY 86-9766 In Subjects With Advanced Cancer, 2011-0327, PI - George R. Blumenschein, Jr., 2011-present

Collaborator, Phase I Open-Label Dose Escalation Study of LJM716 Administered Intravenously in Patients with Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer, 2012-0499, PI - Ana Maria Gonzalez-Angulo, 2012-present

Collaborator, Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors, 2012-0268, PI - George R. Blumenschien, Jr., 2012-present

Collaborator, Phase II, Double-Blind, Placebo-Controlled, Randomized Study of GDC-0941 or GDC-0980 with Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy, 2011-1135, 2012-present

Collaborator, Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination with Trastuzumab in Breast Cancer Patients with Brain Metastases, 2011-0688, PI - Nuhad Ibrahim, 2012-present

Collaborator, A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC 1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2-Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus, 2013-0776, PI - Bora Lim, 2013-present, Millennium

Collaborator, Examination of the Concordance between Oncotype DX and Other Molecular Diagnostic Signatures, PA12-1165, PI - Amy Hong Zhang, 2013-present

Collaborator, Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer, 2013-0375, PI - Stacy Moulder, 2013-present

Collaborator, Phase I, First-in-Human, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of X-396 in patients with advanced solid tumors, 2012-0477, PI - George R. Blumenschein, Jr., 2013-present

Collaborator, Phase IA/IB, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects with Advanced Solid Tumors and He, 2012-0242, PI - George R. Blumenschein, Jr., 2013-present

Principal Investigator, Phase Ib/II Trial of LEE011 in Combination with Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Her2 negative Locally Advanced or Metastatic Breast Cancer, 2013-0468, 2013-present, Novartis

Collaborator, Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis, 2013-0007, PI - Naoto Ueno, 2013-present

Principal Investigator, Phase III Randomized, Placebo-Control Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer, SWOG 1207, 2013-present, PI Funded by the NCI (NCT01674140)

Collaborator, Randomized Pre-Surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole on Primary Breast Cancer, 2013-0534, PI - Funda Meric-Bernstam, 2013-present, ALLIANCE - A011202

Collaborator, Randomized, Multicenter, Double-Blind Phase III Study of Pd-0332991 (Oral Cdk 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal Women with Er (+), Her2 (-) Breast Cancer who have not Received any Prior Systemic Therapy, 2013-0258, PI - Stacy Moulder, 2013-present

Collaborator, A Phase II Trial of HKI-272 (Neratinib) and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases, 2013-1007, PI - Nuhad K Ibrahim, 2014-present, Breast Cancer Research Foundation, Dana Farber, Translational Breast Cancer Research Consortium, Puma Biotechnology, Inc.

Co-Principal Investigator, A Randomized Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer who Received No Prior Therapy for Advanced Disease, 2013-0846, PI - Gabriel N Hortobagyi, 2014-present, Novartis

Collaborator, Assessment of the Tumor Response to Neoadjuvant Chemotherapy in Women with Invasive Breast Cancer using Tc99m sestamibi Molecular Breast Imaging: A Prospective Study., 2014-0812, PI - Gaiane Margishvili Rauch, 2014-present, Diagnostic Imaging Clinical Research Committee Grant

Collaborator, Comparing the Performance of Full-Field Digital Mammography (FFDM), Digital Breast Tomosynthesis (DBT) and Breast MRI in the Preoperative Imaging Evaluation Breast Cancer: A Prospective Study, 2014-0166, PI - Rosalind Pitpitan Candelaria, 2014-present, Diagnostic Imaging Clinical Research Committee Grant

Collaborator, Impact of the Oncotype DX? DCIS Score on Treatment Decision Making in Patients with Ductal Carcinoma in Situ, 2013-0849, PI - Henry Kuerer, 2014-present, Genomic Health, Inc.

Collaborator, Incremental cancer detection utilizing Breast Ultrasound versus Breast MRI in the evaluation of ACR Category 6 breast cancer patients., PA14-0801, PI - Wei Tse Yang, 2014-present

Collaborator, Measurements of Breast Tissue Optical Properties with Diffuse Optical Spectroscopic Imaging (DOSI), 2014-0238, PI - Wei Tse Yang, 2014-present, UCI - Beckman Laser Institute

Collaborator, Ultrasound (US) Imaging Lexicon of Axillary lymph nodes in Patients with Breast Cancer, PA14-0227, PI - Wei Tse Yang, 2014-present

Collaborator, A Companion Sample Collection Protocol to Support the Discovery of the Mechanisms of Resistance to Targeted Cancer Therapies, PA14-1013, PI - Funda Meric-Bernstam, 2015-present, Novartis

Unfunded

Principal Investigator, Long-term outcomes in patients with node-negative invasive breast cancer 1cm or less in greatest diameter (T1a,bN0M0), RCR04-0880, 2005-present

Principal Investigator, Prognostic factors for long-term outcomes in patients with node-negative invasive breast cancer 1cm or less in greater diameter (T1a,bN0M0), LAB05-0457, 2006-present

Principal Investigator, Response to Primary Systemic Chemotherapy: Its effect on long term outcome, RCR07-0159, 2007-present

Co-Principal Investigator, Breast Cancer Evaluation and Targeted Investigational Therapy, LAB11-0337, PI - Ricardo Alvarez, 2011-present

Collaborator, Patterns of care for breast cancer treatment, DR11-0100, PI - Sharon Hermes Giordano, 2011-present

Principal Investigator, Adherence and Treatment-Related Complications in Breast Cancer Patients, PA11-1155, 2012-present

Collaborator, Clinical relevance of additional MDACC Mammography and Ultrasound work up for ACR Category 6 breast cancer patients, PA13-0675, PI - Rosalind Pitpitan Candelaria, 2013-present

Collaborator, Correlating Fine Needle Aspiration to Surgical Excision to Assess for Eradication of Nodal Metastases after Chemotherapy in Breast Cancer, 2013-0877, PI - Abigail Suzanne Caudle, 2013-present

Co-Principal Investigator, Benefits and Risks of Participating in Clinical Trials for Older Cancer Patients, PA14-0028, PI - Sharon Hermes Giordano, 2014-present

Collaborator, Evaluation of biologic markers in determining prognosis in breast cancer patients, PA14-0710, PI - Elizabeth Mittendorf, 2014-present

Collaborator, Patterns, Costs, and Outcomes of Cancer Care, PA14-0949, PI - Sharon Hermes Giordano, 2014-present

Principal Investigator, Time to adjuvant chemotherapy among breast cancer patients in the California Cancer Registry, PA14-0458, 2014-present

  • Enviar a amistad Enviar a amistad
  • Imprimir Imprimir
  • Texto sin formato Texto sin formato

Etiquetado como:

Mariana Chavez Mac Gregor, MD Anderson Cancer Center, bio profesional

Califica este artículo

0